ReviewWorld journal of hepatology2015
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Efficacy and safety of radiofrequency ablation versus minimally invasive liver surgery for small hepatocellular carcinoma: a systematic review and meta-analysis.Surgical endoscopy · 2019Pooled it
- Article
- Arabinogalactan-Functionalized Gold Nanoparticles Demonstrated Remarkable Anticancer Therapeutic Effect against Hepatocellular Carcinoma.Molecular pharmaceutics · 2025Article
- Naringenin: A potential therapeutic agent for modulating angiogenesis and immune response in hepatocellular carcinoma.Journal of pharmaceutical analysis · 2025Article
- Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: A systematic review of current evidence and future prospects (Review).Oncology letters · 2025Review
- Targeted therapy for liver cancer: Current status and future directions.BioImpacts : BI · 2025Review
- Biological Activity of Natural and Synthetic Peptides as Anticancer Agents.International journal of molecular sciences · 2024Review
- Article
- Recent advances in oncolytic virus therapy for hepatocellular carcinoma.Frontiers in oncology · 2023Review
- Targeted Therapy and Personalized Medicine.Cancer treatment and research · 2023Article
- Deciphering Tumour Microenvironment of Liver Cancer through Deconvolution of Bulk RNA-Seq Data with Single-Cell Atlas.Cancers · 2022Article
- A new triazolothiadiazine derivative inhibits stemness and induces cell death in HCC by oxidative stress dependent JNK pathway activation.Scientific reports · 2022Article
- Three-dimensional (3D) cell culture: a valuable step in advancing treatments for human hepatocellular carcinoma.Cancer cell international · 2022Review
- Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular CarcinomaCancers · 2022Article
- Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways.Pharmacology research & perspectives · 2022Article
- E2F1-induced microRNA-224-5p expression is associated with hepatocellular carcinoma cell migration, invasion and epithelial-mesenchymal transition via MREG.Oncology letters · 2022Article
- Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.Journal of biomedical science · 2022Article
- Design, synthesis, and anticancer activity of three novel palbociclib derivatives.Frontiers in oncology · 2022Article
- Three-Dimensional Cell Culture Models of Hepatocellular Carcinoma - a Review.Journal of gastrointestinal cancer · 2021Review
- Emerging treatment modalities for systemic therapy in hepatocellular carcinoma.Biomarker research · 2021Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancer is one of the commonest causes of death. Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers. For patients with unresectable or metastatic HCC, conventional chemotherapy is of limited or no benefit. Sorafenib is the only systemic treatment to demonstrate a statistically significant but modest overall survival benefit, leading to an era of targeted agents. Many clinical trials of targeted drugs have been carried out with many more in progress. Some drugs like PTK787 showed potential benefits in the treatment of HCC. Despite these promising breakthroughs, patients with HCC still have a dismal prognosis. Recently, both a phase III trial of everolimus and a phase II clinical trial of trebananib failed to demonstrate effective antitumor activity in advanced HCC. Sorafenib still plays a pivotal role in advanced HCC, leading to further explorations to exert its maximum efficacy. Combinations targeted with chemotherapy or transarterial chemoembolization is now being tested and might bring about advances. New targeted agents such as mammalian target of rapamycin inhibitors are under investigation, as well as further exploration of the mechanism of hepatocarcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.